Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1321P is a pseudogene copy of the U6 small nuclear RNA gene. While functional U6 snRNA is an essential component of the spliceosome responsible for intron removal in pre-mRNA splicing[1][3], pseudogenes like RNU6-1321P are nonfunctional sequences that result from retrotransposition events and do not produce active RNA molecules[2]. Pseudogenes are generally considered genomic fossils and do not have roles in cellular biology, disease, or drug interactions. There is nothing to indicate that RNU6-1321P acts as a therapeutic target, biomarker, or is directly involved in disease mechanisms. This entry is best classified as a nonfunctional pseudogene derived from a small nuclear RNA gene; thus, it does not meet criteria for a typical drug target, and its mention as a therapeutic target is incorrect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 1321 pseudogene (RNU6-1321P).